H.C. Wainwright raised the firm’s price target on Zevra Therapeutics to $20 from $18 and keeps a Buy rating on the shares after the FDA approved Miplyffa for Niemann-Pick disease type C. The firm believe the approval “will be greeted with enthusiasm in the highly-concentrated NPC community.” It views the news as a “transformative event” for Zevra, as the firm projects peak sales of $250M in the U.S. alone.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZVRA:
- Zevra Therapeutics receives FDA approval for Miplyffa
- Zevra Therapeutics’ MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C
- FDA approves Zevra’s Miplyffa, first treatment for Neimann-Pick disease, type C
- Zevra Therapeutics Inc trading halted, news pending
- Zevra Therapeutics price target lowered to $22 from $24 at Canaccord